Nat. Rev. Nephrol. doi: /nrneph

Slides:

Advertisements

Similar presentations

Date of download: 7/11/2016 From: Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Ann Intern Med. 2013;159(6):

Advertisements

November 3, 2012 N Engl J Med DOI: /NEJMoa

Fredrik Karlsson, MD, Angelo Modica, MD, Thomas Mooe, MD, PhD

The Longitudinal Study of Liver Cysts in Patients With Autosomal Dominant Polycystic Kidney Disease and Polycystic Liver Disease Ryo Matsuura, Kenjiro.

Characteristics IgAN (n=28) ADPKD (n=37) Male (percentage) 21 (75.0)

Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease: Reliable Indicators of Vasopressin Activity and Disease Prognosis?

Current status of end-stage renal disease care in India and Pakistan

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

Figure 4 The theoretical contribution of genetic and

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Physiological changes in the renal system in pregnancy

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Pathogenic mechanisms and pathways in ADPKD

Nat. Rev. Nephrol. doi: /nrneph

Figure 7 The efficacy of phosphate-binder therapy

Olivier Niel, MD, PhD, Charlotte Boussard, MSc, Paul Bastard, MSc

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Podocyte dysfunction is a common feature of renal injury

Figure 1 Acute kidney injury and chronic kidney disease

Current status of end-stage renal disease care in India and Pakistan

Figure 4 Model of changes in the serum levels

Volume 92, Issue 4, Pages (October 2017)

Robert W. Schrier, Kimberly K. McFann, Ann M. Johnson

Triptolide-Containing Formulation in Patients With Autosomal Dominant Polycystic Kidney Disease and Proteinuria: An Uncontrolled Trial Dongping Chen,

Matei Neagu, PhD, Daniel Coca, PhD, Albert C.M. Ong, DM

Nat. Rev. Nephrol. doi: /nrneph

Recurrent AA Amyloidosis in a Kidney Transplant

The urinary metabolome of chronic kidney disease

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument Dorothee Oberdhan, Jason.

Figure 6 Hypothetical effect of starting therapy for autosomal

Your Kidneys May Outlive You

Nat. Rev. Nephrol. doi: /nrneph

Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian, Yan Yan, Ziyad Al-Aly

Figure 2 Sources of data to characterize the ADPKD clinical phenotype

Nat. Rev. Nephrol. doi: /nrneph

Quiz Page July 2012 American Journal of Kidney Diseases

U-shaped effect of eGFR and mortality

Figure 3 Preventive strategies for CSA-AKI

Volume 79, Issue 2, Pages (January 2011)

Beef Tea, Vitality, Creatinine, and the Estimated GFR

Classification by HtTKV0 and age at HtTKV0 predicts the change in eGFR over time in class 1 patients. Classification by HtTKV0 and age at HtTKV0 predicts.

Volume 81, Issue 6, Pages (March 2012)

Volume 76, Issue 3, Pages (August 2009)

Nowak et al. Am J Nephrol 2016;44: (DOI: / )

Methods for guideline development

Copyright © 2013 Elsevier Inc. All rights reserved.

CT of Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: Accuracy, Reproducibility, and Radiation Dose Low-dose CT protocols can yield total.

Volume 85, Issue 5, Pages (May 2014)

Volume 67, Issue 2, Pages (February 2005)

Ann M. O'Hare, MA, MD American Journal of Kidney Diseases

Nat. Rev. Nephrol. doi: /nrneph

Change in total kidney volume and renal function over 3 years of tolvaptan compared with matched control and their correlation for individual subjects.

Figure 1 Relationships between genetic variants, quantitative traits and diseases Figure 1 | Relationships between genetic variants, quantitative traits.

Volume 64, Issue 3, Pages (September 2003)

Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients Miyamoto et al. Am J Nephrol 2017;45:

The pretest probability of disease decreases with age in individuals who are born with 50% risk for autosomal dominant polycystic kidney disease (ADPKD)

Presentation transcript:

Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.127 Figure 3 Theoretical relationship between total kidney volume (TKV) and kidney function Figure 3 | Theoretical relationship between total kidney volume (TKV) and kidney function. Rate of TKV increase (part a), measured TKV (part b) and estimated glomerular filtration rate (eGFR; part c) over time in patients with either mild (blue line, defined as a 1% increase in TKV per year), moderate (red line, defined as a 3% increase in TKV per year) or severe (green line, defined as 5% TKV growth per year) autosomal dominant polycystic kidney disease (ADPKD). The model assumes a TKV of 400 ml at 20 years of age, with a baseline eGFR of 120 ml/min/1.73 m2 and a calculated eGFRt = eGFRt−1 − (TKVt/400). eGFRt is the eGFR at time t in years45. Lanktree, M. B. & Chapman, A. B. (2017) New treatment paradigms for ADPKD: moving towards precision medicine Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.127